GSK360A orally active HIF-PHD inhibitor. GSK360A exerts systemic and local effects by stabilizing HIF-1a signaling and improves long-term ventricular function, remodeling, and vascularity in a model of established ventricular dysfunction. These findings suggest that GSK360A may be suitable for the treatment of post-MI remodeling and heart failure.Form:Beige SolidMelting Point:195-197°CSolubility:Methanol